SNY’s 1Q12 US sales of branded Lovenox were €122M, about $159 at the average exchange rate during the quarter; this figure excludes sales of SNY’s authorized generic, which were not explicitly disclosed (but see below):
For the sake of simplicity, if we assume that all of the 121.9% year-over-year increase in SNY’s US sales of generic drugs came from the Lovenox AG, then SNY’s 1Q12 sales of the Lovenox AG were about €33M or about $43M. This simplifying assumption should be accurate enough for our purposes.
Thus, we have the following breakdown of US Lovenox sales in 1Q12:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.